Mr. Justin Hanka reports

MINDBIO APPOINTS NATIONAL DRUG POLICY & MINING INDUSTRY EXPERT TO LEAD SOUTH AMERICAN MINING INDUSTRY COMMERCIALISATION

Mindbio Therapeutics Corp. has appointed Felipe Leyton -- one of South America's most influential drug and alcohol policy architects and a recognized mining industry safety authority -- to lead commercialization across the South American mining sector.

Mr. Leyton was part of the technical and operational implementation of Chile's landmark Zero Tolerance framework for alcohol-impaired driving and will now spearhead deployment of Mindbio's voice-initiated AI (artificial intelligence) drug and alcohol screening platform into one of the world's largest and highest-risk industrial markets.

This appointment represents a significant inflection point as Mindbio transitions from advanced development to commercial field deployment.

(0.b) National policy architect with deep mining industry access

Mr. Leyton is widely regarded as a leading authority in alcohol and drug public policy, mining industry safety, regulatory implementation, and evidence-based prevention strategy in South America.

He previously served as:

• Head of Chile's National Alcohol Prevention Unit;
• Head of national prevention programs.

He led for several years the technical and operational implementation of Chile's Zero Tolerance alcohol law currently in force, significantly expanding nationwide roadside control coverage and strengthening enforcement capacity. He also contributed to the design and implementation architecture of Chile's national roadside drug testing program, launched in 2019.

Mr. Leyton is currently a partner at TConsulting, advising major Chilean mining operators, government ministries and international organizations on:

• Drug and alcohol prevention strategy;
• Regulatory compliance;
• Workplace health promotion;
• Industrial safety culture transformation.

His combination of national regulatory leadership and direct mining industry engagement positions Mindbio for accelerated enterprise adoption.

(0.c) Strategic commercial mandate

Under his engagement with Mindbio, Mr. Leyton will:

• Develop and finalize mining-specific testing protocols with Mindbio's engineering team;
• Expand clinical validation and refine AI prediction models;
• Strengthen multisubstance detection capability including cocaine, benzodiazepines, amphetamines, cannabis, hallucinogens and alcohol;
• Develop scalable enterprise licensing frameworks for mining operators;
• Oversee phased deployment into active mining environments.

His mandate directly targets commercial revenue generation within the South American mining sector.

(0.d) Edge AI hardware kiosk platform ready for field deployment -- Q2 2026

Mindbio is near completion of the prototype design of its integrated Edge AI hardware-software kiosk system, purpose built for industrial environments.

On-site field testing at mining operations is scheduled to commence in Q2 2026, marking a major commercial milestone.

The platform delivers:

• Rapid, non-invasive screening;
• Real-time artificial-intelligence-driven impairment prediction using voice;
• Scalable on-site deployment;
• Reduced operational friction compared with traditional biological testing methods.

(0.e) Large and urgent safety market opportunity

Substance use remains a significant occupational safety risk in heavy industry.

In Chile alone:

• Alcohol consumption among mining workers exceeds 75 per cent;
• Approximately 40 per cent are classified as problem drinkers;
• Approximately 9 per cent report drug use;
• The mining work force exceeds 200,000 individuals.

Globally, an estimated 20 to 25 per cent of occupational accidents are directly or indirectly linked to substance use (International Labour Organization, 1996; 2022; Gomez et al., 2002).

These data underscore a substantial global opportunity for scalable, real-time impairment detection technologies in safety-critical industries.

Justin Hanka, chief executive officer of Mindbio, stated:

"Mr. Leyton brings exceptional credibility, regulatory authority and direct access to the mining industry. He helped design and implement Chile's Zero Tolerance alcohol framework at a national level, and he now leads the commercialization in a world-first AI voice-based impairment detection platform for mining.

"This marks a transition from technology development to structured commercial deployment. We believe this positions Mindbio at the forefront of next-generation industrial safety solutions and voice-initiated health diagnostic technologies."

Mindbio continues to position itself at the intersection of biotechnology, artificial intelligence and medical diagnostics -- building scalable, non-invasive solutions designed to improve safety outcomes, reduce liability exposure and modernize impairment detection across global high-risk industries.

About Mindbio Therapeutics Corp.

Mindbio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is now collecting data that will allow its prediction tool to work on other types of intoxication for use in consumer and enterprise environments.

We seek Safe Harbor.